J&J to Acquire Firefly Bio, Expanding Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
JNJ sits 56% above its 52-week low of $149.04.
Summary
Johnson & Johnson announced the acquisition of Firefly Bio, Inc., a strategic move to expand its oncology pipeline. This deal brings a novel degrader antibody conjugate platform into J&J's portfolio, aiming to bolster future drug development in a critical therapeutic area. While the financial terms were not disclosed, this acquisition signals J&J's continued investment in innovative cancer treatments.
At the time of this announcement, JNJ was trading at $232.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $560.3B. The 52-week trading range was $149.04 to $251.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.